RxDoctor Payments Data

Justin Strote, MD

Interventional Cardiology · Fort Collins, CONPI 1255388955

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (40.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Edwards Lifesciences accounts for 82.3% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $8,820 and has fallen 79.8% since, to $1,784 in 2025.

$24,381in general payments, 2019–2025

Across 208 payments — averaging $117.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$20K
  • Abbott$2K
  • Boston Scientific$854
  • Medtronic$779
  • Abiomed$570
  • Shockwave Medical, Inc$158
  • plus $80 from 4 others
$2,792,333in research payments, 2019–2025

Across 224 payments — averaging $12,466 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$2.3M
  • Abbott$305K
  • W. L. Gore & Associates, Inc.$139K

What the payments were for

  • Consulting fees$9,82840%
  • Travel & lodging$7,09829%
  • Food & beverage$7,45531%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,381 in reported general payments places this provider in the 75th percentile of 111 interventional cardiology providers in Colorado.

See all interventional cardiology providers in Colorado

Medicare billing

Part B allowed, 2024
$305,411
Medicare patients
1,320
Services billed
2,516

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban180$268,213
JardianceEmpagliflozin94$143,788
XareltoRivaroxaban58$89,149
Repatha SureclickEvolocumab81$77,897
EntrestoSacubitril/Valsartan26$42,067
Praluent PenAlirocumab43$39,992
FarxigaDapagliflozin Propanediol29$34,911
VascepaIcosapent Ethyl12$11,042
Icosapent Ethyl12$5,306
Atorvastatin Calcium445$5,066
Ezetimibe179$4,194
Metoprolol Succinate275$4,064
Rosuvastatin Calcium303$3,170
Losartan Potassium306$3,032
Nebivolol Hcl37$2,264

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Fort Collins

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →